Summary
CI-994 [aka: acetyldinaline; PD 123654; 4-acetylamino-N-(2′aminophenyl)-benzamide] (Figure 1) is a novel antitumor agent with a unique mechanism of action. It is the acetylated metabolite of dinaline, a compound previously identified as having cytotoxic and cytostatic activity against several murine and human xenograft tumor models. CI-994 had activity against 8/8 solid tumors tested (log cell kills at the highest non-toxic dose): pancreatic ductal adenocarcinoma #02 (4.7); pancreatic adenocarcinoma#03 (3.0; 1/6 cures); colon adenocarcinoma #38 (1.6); colon adenocarcinoma #51/A (1.1); mammary adenocarcinoma #25 (1.7); mammary adenocarcinoma #17/ADR (0.5); Dunning osteogenic sarcoma (4.0); and the human prostate carcinoma LNCaP (1.2). CI-994 had the same spectrum of activity in vivo as dinaline. It also behaved similarly in schedule comparison/toxicity trials. Prolonged administration with lower drug doses was more effective than short-term therapy at higher individual doses. If doses were kept between 40 and 60 mg/kg/injection, prolonged administration (> 50 days) was tolerated with no gross toxicity. Doses ≥90 mg/kg/injection caused lethality after 4–5 days of administration. The maximum tolerated total dose was also increased with smaller individual doses administered for prolonged intervals. Clinical Phase I trials are ongoing with this agent.
Similar content being viewed by others
References
Berger MR, Richter H, Seelig MH, Eibl H, Schmahl D: New cytostatics: more activity and less toxicity. Cancer Treat Rev 17:143–154, 1990
Berger MR, Bischoff H, Fritschi E, Henne T, Herrmann M, Pool BL, Satzinger G, Schmahl D, Weiershausen U: Synthesis, toxicity and therapeutic efficacy of 4-amino-N-(2′-aminophenyl) benzamide: a new compound preferentially active in slowly growing tumors. Cancer Treat Rep 69:1415–1424, 1985
Lelieveld P, Middeldorp RJF, Van Putten LM: Effectiveness of P-aminobenzoyl-O-phenylenediamine (GOE 1734) against mouse, rat and human tumor cells. Cancer Chemother Pharmacol 15:88–90, 1985
Berger MR, Schmahl D: Antineoplastic activity of two 4-amino-N-(2′-aminophenyl)benzamide (GOE 1734) derivatives in rat mammary carcinoma. Proc Am Assoc Cancer Res 28:301, 1987
Berger MR, Richter H, Seelig MH, Eibl H, Schmahl D: New cytostatics: more activity and less toxicity. Cancer Treat Rev 17:143–154, 1990
Kraker AJ, Moore CW: Activity and effects of 4-amino-N-(2-aminophenyl)benzamide (GOE 1734, PD 104208): a compound with a novel mechanism of action, against HCT-8. Proc Am Assoc Cancer Res 30:584, 1991
Leopold WR, Hook KE, Fry DW: Activity of biochemical properties of GOE 1734 (PD 104208), an anticancer agent with a novel mechanism of activity. Proc Am Assoc Cancer Res 28:302, 1988
Hagenbeek A, Weiershausen U, Martens ACM: Dinaline: a new oral drug against leukemia? Preclinical studies in a relevant rat model for human acute myelocytic leukemia (BNML). Leukemia (Baltimore) 2:226–230, 1988
Howard C, Roberts B, Vincent P, Elliott W: N-acetyl-dinaline: a small molecule with in vivo cytostatic activity. Proc Am Assoc Cancer Res 33:393, 1992
Rummel SA, Kraker AJ, Steinkampf RW, Hook KE, Klohs WD: Role of a small molecular weight phosphoprotein in the mechanism of action of CI-994 (N-acetyldinaline). Int J Cancer 62:636–642, 1995
Rummel S, Steinkampf R, Auerbach R, Kraker A, Klohs W: Specific loss of a 16 kD phosphoprotein in colon tumor cells treated with the novel antitumor compound CI-994 [4-(acetylamino)-N-(2-aminophenyl)benzamide, N-acetyldinine]. Proc Am Assoc Cancer Res 34:369, 1993
Klohs W, Kraker A, Steinkampf R, Moore C, Dominick M: Mitochondrial involvement in the mechanism of action of the novel antitumor compound 4-(acetylamino)-N(2-aminophenyl)benzamide (PD-123654, GOE 5549). Proc Am Assoc Cancer Res 32:396, 1991
Kraker AJ, Wolven A, Fry DW, Klohs WD: Cell cycle and nucleotide metabolism effects of 4-(acetylamino)-N-(2-aminophenyl) benzamide (PD 123654, GOE 5549) in HCT-8 cells. Proc Am Assoc Cancer Res 32:396, 1991
Rummel SA, Steinkampf RW, Kraker AJ, Klohs WD: The role of protein phosphorylation in the mechanism of 4-(acetylamino)-N-(2-aminophenyl) benzamide (N-Acetyldinaline, CI-994). Proc Am Assoc Cancer Res 33:514, 1992
Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP Jr, Schabel FM Jr: Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of pancreas in C57B1/6 mice. Cancer Res 44:717–726, 1984
Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr: Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 35:2434–2439, 1975
Corbett TH, Leopold WR, Dykes DJ, Roberts BJ, Griswold DP Jr, Schabel FM Jr: Toxicity and anticancer activity of a new triazine antifolate (NSC 127755). Cancer Res 42:1701–1715, 1982
Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr: Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 40:2660–2680, 1977
Corbett TH, Roberts B J, Trader MW Jr, Laster WR Jr, Griswold DP Jr, Schabel FM Jr: Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. Cancer Treat Rep 66(5): 1187–1200, 1982
Hiramoto RN, Ghanta VK: Surgical adjuvant chemotherapy of metastatic murine osteosarcoma. Int J Cancer 25:393–397, 1980
Corbett TH, Valeriote FA, Polin L et al.: Discovery of solid tumor active agents using a soft-agar-colony-formationdisk-diffusion-assay. In: Valeriote FA, Corbett TH, Baker LH (eds), Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development, pp 35–87. Norwell, Massachusetts: Kluwer Academic Publishers, 1992
LoRusso PM, Polin L, Biernat LA, Valeriote FA, Corbett TH: Activity of datelliptium acetate (NSC 311152; SR 95156A) against solid tumors of mice. Invest New Drugs 8:253–261, 1990
Corbett TH, Valeriote FA: Rodent models in experimental chemotherapy. In: Kallman RF (ed), The Use of Rodent Tumors in Experimental Cancer Therapy: Conclusions and Recommendations, pp 233–247. Elmsford, NY: Pergamon Press, 1987
Graziano M, Walsh K: Two-week oral toxicity study of CI-994 in rats. Proc Am Assoc Cancer Res 35:460, 1994
Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE: Quantitative comparison of toxicity of anticancer agents in mouse, rat, dog, monkey and man. Cancer Chemother Rep 50(4):219–244
LoRusso P, Wozniak A, Foster B, Parchment R, Volpe D, Meyer M, Radulovic L, Corbett TH, Valdivieso M: Phase I trial of extended daily dosing of acetyldinaline (CI-994) (abstract). Submitted NCI-EORTC, November 1995
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
LoRusso, P.M., Demchik, L., Foster, B. et al. Preclinical antitumor activity of CI-994. Invest New Drugs 14, 349–356 (1996). https://doi.org/10.1007/BF00180810
Issue Date:
DOI: https://doi.org/10.1007/BF00180810